Literature DB >> 8199570

Varicella zoster infection after bone marrow transplantation: incidence, risk factors and complications.

C S Han1, W Miller, R Haake, D Weisdorf.   

Abstract

The cellular immunoincompetence which follows bone marrow transplantation (BMT) allows both primary and reactivation infection with herpes viruses. We report the overall incidence and timing of varicella zoster virus (VZV) infections after BMT, including the clinical course, complications and associated clinical risk features. Of 1186 patients undergoing BMT through 1989, 216 patients developed VZV infection between 4 days and 10.8 years after BMT; 86% of them within the first 18 months. Of all patients transplanted, 15 +/- 3% by 6 months and 52 +/- 14% by 5 years had developed VZV infection. Dermatomal zoster represented 62% of the infections, while 32% had complicated VZV infection--CNS, disseminated or visceral zoster. All serious infections occurred within 7 months of BMT but only two patients died, both from VZV pneumonitis. Allogeneic and autologous recipients had a similar incidence of VZV infection. VZV seropositive patients had more frequent, earlier and often more complicated or disseminated infections. Age > or = 10 years and radiation in the pre-transplant conditioning were significantly and independently associated with higher rates of VZV infection within a multivariate regression model. Using this model, we could define clinical risk groups with distinctly different hazards of VZV infection: age > 10 years, radiation pre-BMT and VZV seropositive patients had a 44% incidence by 3 years versus age < 10 years, no radiation and VZV seronegative had a 0% incidence by 3 years. Acyclovir assigned for prophylaxis of CMV or HSV infection had no effect on the timing or incidence of VZV infection.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8199570

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  22 in total

1.  High incidence of herpes zoster in nonmyeloablative hematopoietic stem cell transplantation.

Authors:  Shih Hann Su; Valérie Martel-Laferrière; Annie-Claude Labbé; David R Snydman; David Kent; Michel Laverdière; Claire Béliveau; Tanya Logvinenko; Sandra Cohen; Silvy Lachance; Thomas Kiss; Jean Roy
Journal:  Biol Blood Marrow Transplant       Date:  2010-10-25       Impact factor: 5.742

Review 2.  Hematopoietic stem cell transplantation: a primer for the primary care physician.

Authors:  Chantal S Léger; Thomas J Nevill
Journal:  CMAJ       Date:  2004-05-11       Impact factor: 8.262

3.  Immune recovery disease: a case of interstitial keratitis and tonic pupil following bone marrow transplantation.

Authors:  A S Ioannidis; M Forrest; K K Nischal; P Veys; E G Davies; G Woodruff
Journal:  Br J Ophthalmol       Date:  2004-12       Impact factor: 4.638

Review 4.  Central nervous system infection during immunosuppression.

Authors:  Joseph R Zunt
Journal:  Neurol Clin       Date:  2002-02       Impact factor: 3.806

5.  Varicella-zoster virus glycoproteins B and E are major targets of CD4+ and CD8+ T cells reconstituting during zoster after allogeneic transplantation.

Authors:  Patrick Kleemann; Eva Distler; Eva M Wagner; Simone Thomas; Sebastian Klobuch; Steffi Aue; Elke Schnürer; Hansjörg Schild; Matthias Theobald; Bodo Plachter; Stefan Tenzer; Ralf G Meyer; Wolfgang Herr
Journal:  Haematologica       Date:  2011-12-29       Impact factor: 9.941

6.  Long-term acyclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation--a randomized double-blind placebo-controlled study.

Authors:  Michael Boeckh; Hyung W Kim; Mary E D Flowers; Joel D Meyers; Raleigh A Bowden
Journal:  Blood       Date:  2005-11-10       Impact factor: 22.113

7.  Relationship between preexisting anti-varicella-zoster virus (VZV) antibody and clinical VZV reactivation in hematopoietic stem cell transplantation recipients.

Authors:  Masahiro Onozawa; Satoshi Hashino; Mutsumi Takahata; Fumie Fujisawa; Takahito Kawamura; Masao Nakagawa; Kaoru Kahata; Takeshi Kondo; Shuichi Ota; Junji Tanaka; Masahiro Imamura; Masahiro Asaka
Journal:  J Clin Microbiol       Date:  2006-10-11       Impact factor: 5.948

8.  Chronic graft-versus-host disease following varicella-zoster virus infection in allogeneic stem cell transplant recipients.

Authors:  Noriaki Kawano; Hisashi Gondo; Tomohiko Kamimura; Kenichi Aoki; Tadafumi Iino; Fumihiko Ishikawa; Toshihiro Miyamoto; Koji Nagafuji; Kazuya Shimoda; Shin Hayashi; Teruhisa Otsuka; Yukumasa Kazuyama; Mine Harada
Journal:  Int J Hematol       Date:  2003-11       Impact factor: 2.490

9.  High Incidence of Herpes Zoster After Cord Blood Hematopoietic Cell Transplant Despite Longer Duration of Antiviral Prophylaxis.

Authors:  Elisabetta Xue; Hu Xie; Wendy M Leisenring; Louise E Kimball; Sonia Goyal; Lisa Chung; Rachel Blazevic; Byron Maltez; Anna Edwards; Ann E Dahlberg; Rachel B Salit; Colleen Delaney; Steven A Pergam; Michael Boeckh; Filippo Milano; Joshua A Hill
Journal:  Clin Infect Dis       Date:  2021-04-26       Impact factor: 9.079

10.  Molecular evidence for the existence of disseminated zoster as a distinct entity in an immunosuppressed renal transplant patient.

Authors:  E M Schlüpen; H C Korting; F Nachbar; M Volkenandt
Journal:  J Mol Med (Berl)       Date:  1995-10       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.